Mesenchymal Stem Cell-natural Killer Cell Interactions: Evidence That Activated NK Cells Are Capable of Killing MSCs, Whereas MSCs Can Inhibit IL-2-induced NK-cell Proliferation
Overview
Authors
Affiliations
In recent years, mesenchymal stem cells (MSCs) have been shown to inhibit T-lymphocyte proliferation induced by alloantigens or mitogens. However, no substantial information is available regarding their effect on natural killer (NK) cells. Here we show that MSCs sharply inhibit IL-2-induced proliferation of resting NK cells, whereas they only partially affect the proliferation of activated NK cells. In addition, we show that IL-2-activated NK cells (but not freshly isolated NK cells) efficiently lyse autologous and allogeneic MSCs. The activating NK receptors NKp30, NKG2D, and DNAM-1 represented the major receptors responsible for the induction of NK-mediated cytotoxicity against MSCs. Accordingly, MSCs expressed the known ligands for these activating NK receptors-ULBPs, PVR, and Nectin-2. Moreover, NK-mediated lysis was inhibited when IFN-gamma-exposed MSCs were used as target cells as a consequence of the up-regulation of HLA class I molecules at the MSC surface. The interaction between NK cells and MSCs resulted not only in the lysis of MSCs but also in cytokine production by NK cells. These results should be taken into account when evaluating the possible use of MSCs in novel therapeutic strategies designed to improve engraftment or to suppress graft-versus-host disease (GVHD) in bone marrow transplantation.
Valencia J, Yanez R, Muntion S, Fernandez-Garcia M, Martin-Rufino J, Zapata A Front Immunol. 2025; 16:1473788.
PMID: 40034706 PMC: 11872697. DOI: 10.3389/fimmu.2025.1473788.
Cervero-Varona A, Prencipe G, Peserico A, Canciello A, House A, Santos H iScience. 2025; 28(2):111830.
PMID: 39967871 PMC: 11834128. DOI: 10.1016/j.isci.2025.111830.
Extracellular vesicles in tumor immunity: mechanisms and novel insights.
Kuang L, Wu L, Li Y Mol Cancer. 2025; 24(1):45.
PMID: 39953480 PMC: 11829561. DOI: 10.1186/s12943-025-02233-w.
Hoseinzadeh A, Esmaeili S, Sahebi R, Melak A, Mahmoudi M, Hasannia M Stem Cell Res Ther. 2025; 16(1):33.
PMID: 39901306 PMC: 11792531. DOI: 10.1186/s13287-025-04158-z.
Bibliometric mapping of mesenchymal stem cell therapy for bone regeneration from 2013 to 2023.
Chen Q, Su Y, Yang Z, Lin Q, Ke Y, Xing D Front Med (Lausanne). 2025; 11():1484097.
PMID: 39835103 PMC: 11743382. DOI: 10.3389/fmed.2024.1484097.